Psoriatic Arthritis (PsA) usually starts in the 30s.
Learn what Spondyloarthritis means and whom it affects. Consider its related conditions, how the disease can be managed along with facts and figures.
Psoriatic Arthritis (PsA) is treated the same way as Ankylosing Spondyloarthritis (AS) except some medications work for Peripheral SpA only.
We are a National association to advocate for and support those suffering from Ankylosing Spondylitis, Psoriatic Arthritis, and associated Spondyloarthritis diseases. The Canadian Spondylitis Association is run entirely by volunteers with Spondyloarthritis.
About 4.6 million Canadians live with some form of arthritis.
More than 4.6 million Canadians live with a form of arthritis. The pain caused by arthritis to those who live with it is wearing and depressing. Arthritis pain can have a severe effect on work, relationships and quality of life.
There are over 100 types of arthritis.
With a broad offering of Support Groups, awareness and connectivity on Social Networks along with Educational Seminars and Events, the Canadian Spondylitis Association has a strong commitment to supporting the Spondylitis Community.
Psoriatic Arthritis (PsA) patients don’t have as much axial pain as Ankylosing Spondyloarthritis (AS) patients.
Discover the various ways you can participate in the Canadian Spondylitis Association and make an impression on our nation for those who suffer with Spondylitis.
Spondyloarthritis is seronegative. That is, a blood test will not show the presence of RF, Rheumatoid Factor.
Consider the latest news and events from the Canadian Spondylitis Association, and become a part of something that helps 4.6 Million Canadians.
Cosentyx first Interleukin-17A inhibitor for psoriatic arthritis and ankylosing spondylitis approved by Health Canada
A multifaceted approach for the early clinical identification of axial spondyloarthritis: a study of first degree relatives
AS Health Storylines Mobile App, Self-care for Ankylosing Spondylitis and associated Spondyloarthritis diseases
A Canadian research team (including patients, healthcare providers, researchers and policy makers) is exploring new ways to help people with chronic illness live well.
Effective February 2, 2015 the Quebec Ministry of Health advised that a best lowest price policy will apply for Infliximab and its indications (what diseases it is approved to treat).
This article highlights the guidelines for Rheumatologists in the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) & ankylosing spondylitis (AS).
Join our mailing list and be the first to hear about news, events and research.